AU2011330850B2 - Inhibitors of HIV replication - Google Patents

Inhibitors of HIV replication Download PDF

Info

Publication number
AU2011330850B2
AU2011330850B2 AU2011330850A AU2011330850A AU2011330850B2 AU 2011330850 B2 AU2011330850 B2 AU 2011330850B2 AU 2011330850 A AU2011330850 A AU 2011330850A AU 2011330850 A AU2011330850 A AU 2011330850A AU 2011330850 B2 AU2011330850 B2 AU 2011330850B2
Authority
AU
Australia
Prior art keywords
methyl
compound
mmol
tert
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011330850A
Other languages
English (en)
Other versions
AU2011330850A1 (en
Inventor
Andrew Simon Bell
David Cameron Pryde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK Ltd
Original Assignee
ViiV Healthcare UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK Ltd filed Critical ViiV Healthcare UK Ltd
Publication of AU2011330850A1 publication Critical patent/AU2011330850A1/en
Application granted granted Critical
Publication of AU2011330850B2 publication Critical patent/AU2011330850B2/en
Priority to AU2016202565A priority Critical patent/AU2016202565A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2011330850A 2010-11-15 2011-11-01 Inhibitors of HIV replication Ceased AU2011330850B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016202565A AU2016202565A1 (en) 2010-11-15 2016-04-22 Inhibitors of hiv replication

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41361810P 2010-11-15 2010-11-15
US61/413,618 2010-11-15
US201161485355P 2011-05-12 2011-05-12
US61/485,355 2011-05-12
PCT/IB2011/054852 WO2012066442A1 (en) 2010-11-15 2011-11-01 Inhibitors of hiv replication

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016202565A Division AU2016202565A1 (en) 2010-11-15 2016-04-22 Inhibitors of hiv replication

Publications (2)

Publication Number Publication Date
AU2011330850A1 AU2011330850A1 (en) 2013-06-27
AU2011330850B2 true AU2011330850B2 (en) 2016-01-28

Family

ID=44999830

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011330850A Ceased AU2011330850B2 (en) 2010-11-15 2011-11-01 Inhibitors of HIV replication
AU2016202565A Abandoned AU2016202565A1 (en) 2010-11-15 2016-04-22 Inhibitors of hiv replication

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016202565A Abandoned AU2016202565A1 (en) 2010-11-15 2016-04-22 Inhibitors of hiv replication

Country Status (15)

Country Link
US (3) US8809363B2 (enExample)
EP (1) EP2640729B1 (enExample)
JP (2) JP5902704B2 (enExample)
CN (2) CN103429595B (enExample)
AR (1) AR083870A1 (enExample)
AU (2) AU2011330850B2 (enExample)
BR (1) BR112013011991A2 (enExample)
CA (1) CA2817896A1 (enExample)
CL (1) CL2013001338A1 (enExample)
MX (1) MX343274B (enExample)
RU (1) RU2564445C2 (enExample)
TW (1) TWI445709B (enExample)
UY (1) UY33729A (enExample)
WO (1) WO2012066442A1 (enExample)
ZA (1) ZA201303433B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
PH12013500015A1 (en) 2010-07-02 2013-02-18 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
BR112013011737A2 (pt) 2010-11-15 2016-08-09 Univ Leuven Kath composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
CN103429595B (zh) * 2010-11-15 2015-10-21 Viiv保健英国有限公司 Hiv复制的抑制剂
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
WO2013062028A1 (ja) 2011-10-25 2013-05-02 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US9096586B2 (en) 2012-04-20 2015-08-04 Gilead Sciences, Inc. Therapeutic compounds
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
US9663536B2 (en) 2013-03-13 2017-05-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US9580431B2 (en) 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP2016512507A (ja) 2013-03-13 2016-04-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヒト免疫不全ウイルス複製の阻害剤
JP6268656B2 (ja) 2013-03-14 2018-01-31 ビーブ・ヘルスケア・ユーケイ・（ナンバー５）・リミテッドＶｉｉＶ Ｈｅａｌｔｈｃａｒｅ ＵＫ （Ｎｏ．５） Ｌｉｍｉｔｅｄ ヒト免疫不全ウイルス複製の阻害剤
EP2970274B1 (en) 2013-03-14 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
MX2015016771A (es) 2013-06-25 2016-03-31 Squibb Bristol Myers Co Compuestos de carbazol carboxamida utiles como inhibidores de cinasa.
TWI648272B (zh) 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 經取代之四氫咔唑及咔唑甲醯胺化合物
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
ES2654242T3 (es) 2014-02-12 2018-02-12 Viiv Healthcare (No.5) Limited Macrociclos de benzotiazol como inhibidores de la réplica del virus de la inmunodeficiencia humana
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126743A1 (en) 2014-02-18 2015-08-27 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9932353B2 (en) 2014-02-18 2018-04-03 Viiv Healthcare Uk (No. 5) Limited Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
EP3107913B1 (en) 2014-02-19 2018-07-04 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2015174511A1 (ja) 2014-05-16 2015-11-19 塩野義製薬株式会社 Ｈｉｖ複製阻害作用を有する３環性複素環誘導体
AR102426A1 (es) 2014-10-24 2017-03-01 Bristol Myers Squibb Co Compuestos de indolcarboxamida como inhibidores de btk
PE20171239A1 (es) 2014-10-24 2017-08-24 Bristol Myers Squibb Co Derivados de carbazol
EA031614B1 (ru) 2014-10-24 2019-01-31 Бристол-Майерс Сквибб Компани Трициклические атропоизомерные соединения
EP3294277B1 (en) 2015-05-08 2021-01-20 Katholieke Universiteit Leuven Functional cure of retroviral infection
EP3305789A4 (en) 2015-05-29 2018-11-21 Shionogi & Co., Ltd. Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity
CN111018912A (zh) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 一种抗病毒药物关键中间体的合成和纯化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010130842A1 (en) * 2009-05-15 2010-11-18 Katholieke Universiteit Leuven Thieno [2, 3-b] pyridine derivatives as viral replication inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5489586A (en) * 1994-03-07 1996-02-06 Warner-Lambert Company Method for treating inflammatory disease in humans
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU2001277731A1 (en) * 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
JP2003171381A (ja) 2001-09-25 2003-06-20 Takeda Chem Ind Ltd エントリー阻害剤
JP2003119137A (ja) 2001-10-10 2003-04-23 Japan Tobacco Inc Ｈｉｖ阻害剤
SI1441734T1 (sl) 2001-10-26 2007-08-31 Angeletti P Ist Richerche Bio Dihidropirimidin karboksamidni inhibitorji HIV-integraze
JP4497347B2 (ja) 2001-12-05 2010-07-07 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する誘導体
JP2005515206A (ja) 2001-12-12 2005-05-26 ブリストル−マイヤーズ　スクイブ　カンパニー Ｈｉｖインテグラーゼ・インヒビター
CN100448444C (zh) 2001-12-21 2009-01-07 泰博特克药品有限公司 含杂环取代苯基的磺酰胺广谱hiv蛋白酶抑制剂
ES2291642T3 (es) 2002-01-17 2008-03-01 MERCK & CO., INC. Hidroxinaftiridinoncarboxamidas utiles como inhibidores de la integrasa de vih.
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
US7875604B2 (en) * 2004-02-04 2011-01-25 University Of Virginia Patent Foundation Compounds that inhibit HIV particle formation
MX2007007026A (es) * 2004-12-17 2007-07-04 Hoffmann La Roche Derivados de tieno-piridina como intensificadores alostericos de gaba-b.
EP2574610A1 (en) * 2007-11-15 2013-04-03 Gilead Sciences, Inc. Inhibitors of human immonodeficiency virus replication
RU2402531C2 (ru) * 2008-09-24 2010-10-27 Александр Леонидович Гинцбург Биологически активные вещества, подавляющие патогенные бактерии
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
KR101483834B1 (ko) 2009-12-23 2015-01-16 카트호리이케 유니버시타이트 로이펜 항바이러스 화합물
CN103429595B (zh) * 2010-11-15 2015-10-21 Viiv保健英国有限公司 Hiv复制的抑制剂
BR112013011737A2 (pt) 2010-11-15 2016-08-09 Univ Leuven Kath composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
US9029391B2 (en) 2011-01-24 2015-05-12 Viiv Healthcare Uk Limited Isoquinoline compounds and methods for treating HIV
EP2731436B1 (en) 2011-07-15 2017-03-08 VIIV Healthcare UK Limited 2-(pyrrolo[2,3-b]pyridine-5-yl)-2-(t-butoxy)-acetic acid derivatives as hiv replication inhibitors for the treatment of aids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010130842A1 (en) * 2009-05-15 2010-11-18 Katholieke Universiteit Leuven Thieno [2, 3-b] pyridine derivatives as viral replication inhibitors

Also Published As

Publication number Publication date
TW201300395A (zh) 2013-01-01
CN103429595B (zh) 2015-10-21
US20140315927A1 (en) 2014-10-23
CA2817896A1 (en) 2012-05-24
JP5902704B2 (ja) 2016-04-13
US20120136023A1 (en) 2012-05-31
CN105330675A (zh) 2016-02-17
EP2640729B1 (en) 2016-12-21
CN103429595A (zh) 2013-12-04
AR083870A1 (es) 2013-03-27
RU2564445C2 (ru) 2015-10-10
EP2640729A1 (en) 2013-09-25
WO2012066442A1 (en) 2012-05-24
MX2013005486A (es) 2013-12-12
CL2013001338A1 (es) 2014-03-28
US8809363B2 (en) 2014-08-19
BR112013011991A2 (pt) 2016-08-30
AU2011330850A1 (en) 2013-06-27
US20160355528A1 (en) 2016-12-08
TWI445709B (zh) 2014-07-21
JP2013542247A (ja) 2013-11-21
US9447116B2 (en) 2016-09-20
UY33729A (es) 2012-06-29
ZA201303433B (en) 2014-12-23
MX343274B (es) 2016-10-31
AU2016202565A1 (en) 2016-05-19
JP2016164163A (ja) 2016-09-08
RU2013121788A (ru) 2014-12-27

Similar Documents

Publication Publication Date Title
EP2640729B1 (en) Inhibitors of hiv replication
KR102857816B1 (ko) 포스포이노시티드 3-키나제 (pi3k) 조정과 연관된 질환의 치료를 위한 pi3k의 알로스테릭 크로메논 억제제
ES3025032T3 (en) Carboxy-benzimidazole glp-1r modulating compounds
KR101483834B1 (ko) 항바이러스 화합물
CA2850881C (en) Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
EP3704120A1 (en) Heterocyclic compounds as prmt5 inhibitors
AU2018224488A1 (en) Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2017133667A1 (en) Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
JP2016508150A (ja) ウイルス感染症を処置するための治療用化合物
CA3050625A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
AU2011367809A1 (en) Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
AU2014229762A1 (en) New compounds
JP2020503352A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
US9975888B2 (en) Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
TW202444351A (zh) 聯芳基衍生物及相關用途
CA3173569C (en) Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
HK1173994A (en) Novel antiviral compounds

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BELL, ANDREW SIMON AND PRYDE, DAVID CAMERON

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired